Key result
Prior SSRI use is not linked to lower in-hospital mortality among COVID-19 patients.
Why the study?
Selective serotonin reuptake inhibitors have anti-inflammatory effects and preliminary evidence suggested their potential utility in reducing the impact of COVID-19.
Does prevalent use of selective serotonin reuptake inhibitors reduce in-hospital mortality in adult patients hospitalized with COVID-19?
Cohort (n=1,689)
No
Does prevalent use of selective serotonin reuptake inhibitors reduce in-hospital mortality in adult patients hospitalized with COVID-19?
Prevalent use of SSRIs does not appear to reduce in-hospital mortality among adult patients hospitalized with COVID-19.
Answers are grounded in this paper and cite their sources.
Does not support SSRI repurposing for COVID-19 mortality reduction; leaves open any role pending randomized trials.
PURPOSE/BACKGROUND: Since the emergence of the coronavirus disease 2019 (COVID-19), many efforts have been made to prevent and to treat the disease. In this line, the anti-inflammatory effect of selective serotonin reuptake inhibitors (SSRI) as alternatives for treating chronic inflammatory diseases has been studied. There is previous evidence of the usefulness of these drugs for reducing COVID-19 impact. METHODS/PROCEDURES: We conducted a retrospective single-center cohort study of adult patients with a positive reverse transcriptase-polymerase chain reaction for COVID-19, evaluating the association between SSRI use and in-hospital mortality. FINDINGS/RESULTS: Of 1689 included patients, 182 (10.8%) were exposed to SSRI. A total of 291 patients died during the hospitalization, representing an in-hospital mortality of 17.2% (95% confidence interval [CI], 15.4%-19.0%): 44 (24.2%) of the exposed to SSRIs versus 247 (16.4%) of those not exposed to SSRIs (crude odds ratio [OR], 1.62; 95% CI, 1.12-2.34; P = 0.009). No independent effect of SSRIs on in-hospital mortality was found when applying either the inverse probability of treatment weighting (OR, 1.15; 95% CI, 0.71-1.89; P = 0.56) or with conventional multivariable analysis 0.81 (95 % CI: 0.28-2.31, P = 0.69). IMPLICATIONS/CONCLUSIONS: In the present retrospective study of patients hospitalized for COVID-19, prior use of SSRIs did not reduce mortality.
No takes yet. Share an insight, caveat, or question.
Osores et al. (2023) conducted a cohort in COVID-19 (n=1,689). Selective serotonin reuptake inhibitors (SSRI) vs. No SSRI exposure was evaluated on In-hospital mortality (OR 1.15, 95% CI 0.71-1.89, p=0.56). Prior use of SSRIs did not reduce in-hospital mortality among adult patients hospitalized for COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: